TG Therapeutics, Inc. (NASDAQ:TGTX) management will conduct a conference call for 10th August 2020 at 8:30 AM Eastern Time to discuss financial results and companys performance for 2Q20.
The conference call will also be available live on the website www.tgtherapeutics.com
Earnings Expectation
TG Therapeutics, Inc. is reporting second quarter financial results on Monday 10th August 2020, before market open.
According to analysts surveyed by Thomson Reuters, TGTX is expected to report 2Q20 loss of $ 0.34 per share from revenue of $ 0.03 million.
For the full year, analysts anticipate top line of $ 7.59 million, while looking forward to loss of $ 1.57 per share bottom line.
TG Therapeutics, Inc., a biopharmaceutical company, engages in developing and delivering medicines for patients with chronic lymphocytic leukemia (CLL), non-Hodgkins Lymphoma (NHL), and Multiple Sclerosis (MS). It develops a robust B-cell directed research and development platform for identification of key B-cell pathways of interest and rapid clinical testing. The company has five B-cell targeted drug candidates in clinical development, with the lead two therapies, such as Ublituximab and Umbralisib in pivotal trials for CLL, NHL, and MS.
